SERO-TET
June 7, 2013
LIV. 52 DS
May 23, 2022
URSOFLOR
Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases:
1) protection of injured cholangiocytes against toxic effects of bile acids
2) stimulation of impaired biliary secretion
3) stimulation of detoxification of hydrophobic bile
Description
Indications:
- Treatment of primary biliary cirrhosis (PBC)
- Used to dissolution of radiolucent gallstones in patients with a functioning gall bladder
- Hepatobiliary disorders associated with cystic fibrosis in children aged 6 to 18 years.
Dosage:
- The dosage should be calculated based on the patient's body weight.
- Usual dosage: 8 to 10 mg/kg/day
Mechanism of action:
Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases:- protection of injured cholangiocytes against toxic effects of bile acids
- stimulation of impaired biliary secretion
- stimulation of detoxification of hydrophobic bile
Additional information
| Brand Name | |
|---|---|
| Generic Name | |
| Dosage Form | |
| Administration | |
| License Holder | |
| Key Ingredient |
OFFICE
No.27, Sharifi St. North Gandi Ave. Tehran,Iran.
Post Code: 1969813638
Tel: +98 21 88 650 472 4
Fax: +98 21 88 780 628
E-mail: info@ahranco.com
